EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Low-Dose Propranolol versus Amitriptyline for Episodic Migraine Prophylaxis: A Randomized Controlled Trial Assessing Efficacy, Safety, and Cost-Effectiveness

Vandana Roy, Nasra Banu, Girish Gulab Meshram, Debashish Chowdhury

Clinical Drug Investigation · 2025

DOI: 10.1007/s40261-025-01481-4 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Drug Investigation, 2025. Verfasst von Vandana Roy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Maulana Azad Medical College and Associated Hospitals, New Delhi, 110002, India. roy.vandana@gmail.com. Hauptthemen laut MEDLINE: Amitriptyline, Migraine Disorders, Propranolol. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Direct head-to-head evidence of propranolol and amitriptyline for migraine prophylaxis is limited. This clinical trial compared the efficacy, safety, and cost-effectiveness of low-dose propranolol versus amitriptyline for episodic migraine prophylaxis over a 3-month period. METHODS: This randomized, controlled, open-label, prospective, parallel, single-center trial was conducted at a tertiary care hospital in India. A total of 60 prophylaxis-naïve patients with episodic migraine were randomized 1:1 to receive either low-dose propranolol (80 mg/day) or amitriptyline (10 mg/day). The primary outcome was the improvement in the monthly headache frequency at 3 months from baseline, while the secondary outcomes included improvements from baseline in the proportions of patients achieving a ≥ 50% reduction in monthly headache days, headache severity, headache-induced disability, monthly rescue medication intake, quality of life, and cost-effectiveness (measured by the average cost-effectiveness ratio [ACER] and incremental cost-effectiveness ratio [ICER]). RESULTS: At 3 months, propranolol showed a significantly greater reduction in monthly headache frequency compared with amitriptyline (- 3.67 ± 1.47 versus - 2.87 ± 1.36 days, P = 0.03). More patients in the propranolol group (60%) achieved a ≥ 50% reduction in monthly headache days compared with the amitriptyline group (43.33%) (P = 0.02). Propranolol also showed a greater reduction in monthly rescue medication intake (P = 0.01), but differences in headache severity, headache-induced disability, and quality of life were not significant. Both groups experienced mild adverse drug reactions. Cost-effectiveness analysis revealed propranolol had a higher ACER (US $5.44) and ICER (US $0.40/1% reduction) than amitriptyline. CONCLUSIONS: In our trial, low-dose propranolol demonstrated superior efficacy to amitriptyline in episodic migraine prophylaxis. Both drugs were well tolerated. Our study suggests that amitriptyline was more cost-effective than propranolol. TRIAL REGISTRATION NUMBER: Clinical Trial Registry-India (Date: 27 October 2020; registration no.: CTRI/2020/01/022972).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmitriptylineMigraine DisordersPropranololHumansCost-Benefit AnalysisMaleFemaleAdultProspective StudiesIndiaTreatment OutcomeMiddle AgedYoung AdultDose-Response Relationship, DrugQuality of LifeAnalgesics, Non-Narcotic

Substanzen

AmitriptylinePropranololAnalgesics, Non-Narcotic

Autor:innen und Institutionen

  • Department of Pharmacology, Maulana Azad Medical College and Associated Hospitals, New Delhi, 110002, India. roy.vandana@gmail.com.
  • Department of Pharmacology, Maulana Azad Medical College and Associated Hospitals, New Delhi, 110002, India.
  • Department of Neurology, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research, New Delhi, 110002, India.

Zitieren

APA

Roy, V., Banu, N., Meshram, G. G., & Chowdhury, D. (2025). Low-Dose Propranolol versus Amitriptyline for Episodic Migraine Prophylaxis: A Randomized Controlled Trial Assessing Efficacy, Safety, and Cost-Effectiveness. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01481-4

Vancouver

Roy V, Banu N, Meshram GG, Chowdhury D. Low-Dose Propranolol versus Amitriptyline for Episodic Migraine Prophylaxis: A Randomized Controlled Trial Assessing Efficacy, Safety, and Cost-Effectiveness. Clinical Drug Investigation. 2025. doi:10.1007/s40261-025-01481-4

BibTeX
@article{Roy2025,
  author = {Roy, Vandana and Banu, Nasra and Meshram, Girish Gulab and Chowdhury, Debashish},
  title = {Low-Dose Propranolol versus Amitriptyline for Episodic Migraine Prophylaxis: A Randomized Controlled Trial Assessing Efficacy, Safety, and Cost-Effectiveness},
  journal = {Clinical Drug Investigation},
  year = {2025},
  doi = {10.1007/s40261-025-01481-4}
}
Kostenlos starten →